WO2008076333A3 - Polymer-drug conjugates with tether groups for controlled drug delivery - Google Patents

Polymer-drug conjugates with tether groups for controlled drug delivery Download PDF

Info

Publication number
WO2008076333A3
WO2008076333A3 PCT/US2007/025551 US2007025551W WO2008076333A3 WO 2008076333 A3 WO2008076333 A3 WO 2008076333A3 US 2007025551 W US2007025551 W US 2007025551W WO 2008076333 A3 WO2008076333 A3 WO 2008076333A3
Authority
WO
WIPO (PCT)
Prior art keywords
tether
polymer
relates
present
drug conjugates
Prior art date
Application number
PCT/US2007/025551
Other languages
French (fr)
Other versions
WO2008076333A8 (en
WO2008076333A9 (en
WO2008076333A2 (en
Inventor
Mark E Davis
Jungyeon Hwang
Tianyi Ke
Jing-Jou Lim
Thomas Schluep
Original Assignee
Insert Therapeutics Inc
Mark E Davis
Jungyeon Hwang
Tianyi Ke
Jing-Jou Lim
Thomas Schluep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insert Therapeutics Inc, Mark E Davis, Jungyeon Hwang, Tianyi Ke, Jing-Jou Lim, Thomas Schluep filed Critical Insert Therapeutics Inc
Priority to EP07853378A priority Critical patent/EP2107910A2/en
Priority to JP2009541386A priority patent/JP2010516625A/en
Publication of WO2008076333A2 publication Critical patent/WO2008076333A2/en
Publication of WO2008076333A8 publication Critical patent/WO2008076333A8/en
Publication of WO2008076333A9 publication Critical patent/WO2008076333A9/en
Publication of WO2008076333A3 publication Critical patent/WO2008076333A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Abstract

The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The tether comprises a self-cyclizing moiety, such as -S-CH2-CH2- CO-, -NR-CH2-CH2-NR-CO- and -S-CH2-CH2-NR-CO-. The present invention also relates to drug conjugates comprising cyclodextrin-based polymers.
PCT/US2007/025551 2006-12-13 2007-12-14 Polymer-drug conjugates with tether groups for controlled drug delivery WO2008076333A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07853378A EP2107910A2 (en) 2006-12-13 2007-12-14 Polymer-drug conjugates with tether groups for controlled drug delivery
JP2009541386A JP2010516625A (en) 2007-01-24 2007-12-14 Polymer-drug conjugates with tether groups for controlled drug delivery

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87457206P 2006-12-13 2006-12-13
US60/874,572 2006-12-13
US89709607P 2007-01-24 2007-01-24
US60/897,096 2007-01-24
US275207P 2007-11-09 2007-11-09
US61/002,752 2007-11-09

Publications (4)

Publication Number Publication Date
WO2008076333A2 WO2008076333A2 (en) 2008-06-26
WO2008076333A8 WO2008076333A8 (en) 2008-12-04
WO2008076333A9 WO2008076333A9 (en) 2009-01-29
WO2008076333A3 true WO2008076333A3 (en) 2009-04-09

Family

ID=39110699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025551 WO2008076333A2 (en) 2006-12-13 2007-12-14 Polymer-drug conjugates with tether groups for controlled drug delivery

Country Status (3)

Country Link
EP (1) EP2107910A2 (en)
TW (2) TW201509433A (en)
WO (1) WO2008076333A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
CA2989616A1 (en) * 2008-05-23 2009-11-26 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
EP2525831B1 (en) * 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2571525A4 (en) * 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases
US20120295866A1 (en) * 2011-04-13 2012-11-22 NuTek Pharma Ltd. Synthesis And Use Of Glycoside Pro-Drug Analogs
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR101972303B1 (en) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
DK3210627T3 (en) 2012-07-12 2023-03-13 Hangzhou Dac Biotech Co Ltd CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP6133431B2 (en) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
KR102087850B1 (en) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
PT3122757T (en) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Charged linkers and their uses for conjugation
CN113350518A (en) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 Conjugated bridge linkers to cell binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
TWI548391B (en) * 2015-12-01 2016-09-11 財團法人工業技術研究院 Bone implant and manufacturing method thereof
WO2017205901A1 (en) * 2016-05-31 2017-12-07 Commonwealth Scientific And Industrial Research Organisation Hydrophilic polymer conjugate with multiple antiviral agents for treating a viral infection
CN116143678A (en) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof
US10713677B2 (en) * 2017-12-13 2020-07-14 Mastercard Asia/Pacific Pte. Ltd. Method and system for social savings platform via blockchain
AU2019452577B2 (en) 2019-06-29 2023-08-24 Hangzhou Dac Biotech Co., Ltd. Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
CN111499875A (en) * 2020-04-13 2020-08-07 华东师范大学 Graft copolymer containing cell-penetrating peptide, dopa and reductive detachable PEG (polyethylene glycol) as well as synthetic method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2004019993A1 (en) * 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1525890A1 (en) * 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277551B1 (en) * 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2004019993A1 (en) * 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1525890A1 (en) * 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOPIN A ET AL: "NEW CHEMICAL ADAPTOR UNIT DESIGNED TO RELEASE A DRUG FROM A TUMOR TARGETING DEVICE BY ENZYMATIC TRIGGERING", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, 1 January 2004 (2004-01-01), pages 1853 - 1858, XP008036158, ISSN: 0968-0896 *
GROOT DE FRANCISCUS M H ET AL: "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, vol. 66, 1 January 2001 (2001-01-01), pages 8815 - 8830, XP002212035, ISSN: 0022-3263 *
See also references of EP2107910A2 *
SHABAT D ET AL: "Chemical adaptor systems", CHEMISTRY - A EUROPEAN JOURNAL, VCH PUBLISHERS, vol. 10, 22 March 2004 (2004-03-22), pages 1 - 9, XP002298470, ISSN: 0947-6539 *
TIJERINA MONICA ET AL: "Mechanisms of cytotoxicity in human ovarian carcinoma cells exposed to free Mce6 or HPMA copolymer-Mce6 conjugates.", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 77, no. 6, June 2003 (2003-06-01), pages 645 - 652, XP002488384, ISSN: 0031-8655 *
VRUEH DE R L A ET AL: "SYNTHESIS OF A LIPOPHILIC PRODRUG OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADE NINE (PMEA) AND ITS INCORPORATION INTO A HEPATOCYTE-SPECIFIC LIPIDIC CARRIER", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 16, no. 8, 1 August 1999 (1999-08-01), pages 1179 - 1185, XP008037083, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
EP2107910A2 (en) 2009-10-14
TW200838560A (en) 2008-10-01
TW201509433A (en) 2015-03-16
TWI528976B (en) 2016-04-11
WO2008076333A8 (en) 2008-12-04
WO2008076333A9 (en) 2009-01-29
WO2008076333A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
HK1254600A1 (en) Cyclodextrin-based polymers for delivering covalently attached camptothecin
WO2007004067A3 (en) Methods and compositions for the delivery of biologically active agents
WO2006089007A3 (en) Cyclodextrin-based polymers containing photocleavable linkers for drug delivery
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
WO2006060533A3 (en) Conjugates of 1, 8-bis-naphthalimides with an antibody
WO2009141826A3 (en) Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2007064345A3 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
WO2010091192A3 (en) Nanoscale platinum compounds and methods of use thereof
WO2010075423A3 (en) Dendrimer based modular platforms
WO2005014024A3 (en) Conjugates of a polymer and a protein linked by an oxime linking group
WO2005023294A3 (en) Polyacetal drug conjugates as release system
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
WO2009095479A3 (en) Prodrug comprising a self-cleavable linker
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
CY1112278T1 (en) Cytotoxic agents containing new tomomycin derivatives and their therapeutic use
WO2008053362A3 (en) Bioresponsive polymers
WO2007016380A3 (en) Cyclitol linker polymer conjugate
WO2009089542A3 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009123934A3 (en) Branched multifunctional nanoparticle conjugates and their use
WO2008017381A8 (en) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
MX341715B (en) Self-assembling amphiphilic polymers as anticancer agents.
AU2003250391A1 (en) Conjugates of biocompatible polymers with nuclide activation therapy reagents
WO2008008387A9 (en) Drug delivery polyanhydride composition and method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853378

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009541386

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4563/DELNP/2009

Country of ref document: IN

Ref document number: 2007853378

Country of ref document: EP